Drug intelligence / Profile preview

CSCC_ASCs

Development stage
Unknown
Lead developer
Rigshospitalet
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

CSCC_ASCs is an investigational allogeneic cell therapy consisting of adipose-derived mesenchymal stromal cells (ASCs) developed by the Cardiology Stem Cell Centre (CSCC) at Rigshospitalet, University Hospital of Copenhagen. The product is manufactured from healthy donor abdominal adipose tissue, expanded in bioreactors, and cryopreserved under Good Manufacturing Practice (GMP) conditions. CSCC_ASCs are designed to treat severe respiratory distress in COVID-19 patients by modulating the excessive immune response and cytokine storm associated with the disease. The therapy leverages the immunomodulatory and regenerative properties of mesenchymal stromal cells to reduce lung inflammation and promote tissue repair. Beyond COVID-19, CSCC_ASCs have been evaluated for applications in ischemic heart failure and lung transplantation.

Other names
Allogeneic adipose-derived mesenchymal stromal cellsAdipose-derived stem cells-RigshospitaletCSCC_ASC

Beyond the preview

Go deeper on CSCC_ASCs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSCC_ASCs.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call